Agree. Uplisting isn't going to be the magic bullet. RXMD has to focus some attention on their investors concerns and get us results/answers. For a company to seemingly do so well yet have a lousy SP and IR..... We need something. We use to have at least 3 news releases per month. IS one the new normal? Going in the wrong direction folks. Or maybe there is a reason......
This stock is like watching grass grow. Sorry folks the uplist will not benefit the shareholder too much Maybe a pop but it will be back an undervalued state. Mars really has an handoffs off approach to the stock performance.
I am guessing that the best way to increase the share price would be promotion? Paid promotion?
I feel like RXMD is very sensitive to promoting their stock. But it seems like there are plenty of hard facts to promote. As long as it is not unfounded, pie-in-the-sky, unrealistic projections that might get noticed by the SEC.